Glycosylation, the covalent attachment of carbohydrate structures onto proteins, is the most abundant post-translational modification 1 . Over 50% of human proteins are glycosylated, which alters their activities in diverse fundamental biological processes 2,3 . Despite the importance of glycosylation in biology 4 , the identification and functional validation of complex glycoproteins has remained largely unexplored. Here we develop a novel quantitative approach to identify intact glycopeptides from comparative proteomic data sets, allowing us not only to infer complex glycan structures but also to directly map them to sites within the associated proteins at the proteome scale. We apply this method to human and mouse embryonic stem cells to illuminate the stem cell glycoproteome. This analysis nearly doubles the number of experimentally confirmed glycoproteins, identifies previously unknown glycosylation sites and multiple glycosylated stemness factors, and uncovers evolutionarily conserved as well as speciesspecific glycoproteins in embryonic stem cells. The specificity of our method is confirmed using sister stem cells carrying repairable mutations in enzymes required for fucosylation, Fut9 and Slc35c1. Ablation of fucosylation confers resistance to the bioweapon ricin 5, 6 , and we discover proteins that carry a fucosylation-dependent sugar code for ricin toxicity. Mutations disrupting a subset of these proteins render cells ricin resistant, revealing new players that orchestrate ricin toxicity. Our comparative glycoproteomics platform, SugarQb, enables genome-wide insights into protein glycosylation and glycan modifications in complex biological systems.
, and we discover proteins that carry a fucosylation-dependent sugar code for ricin toxicity. Mutations disrupting a subset of these proteins render cells ricin resistant, revealing new players that orchestrate ricin toxicity. Our comparative glycoproteomics platform, SugarQb, enables genome-wide insights into protein glycosylation and glycan modifications in complex biological systems.
Current glycoproteomics technologies are often limited to the identification and quantification of de-glycosylated peptides 7 , require laborious generation of sample-specific spectral libraries 8 , or rely on dedicated instrumentation and data-acquisition regimes in conjunction with specialized proprietary commercial data analysis tools 9 . Here, we have developed a glycoproteomics approach by complementing established shotgun proteomic workflows 10 with novel computational tools for the interrogation of glycopeptides. Our workflow enriches for glycopeptides after cell lysis and proteolysis using hydrophilic interaction chromatography (HILIC), followed by nano-liquid chromatography electrospray-ionization tandem mass spectrometry (nLC-ESI-MS/MS) using higher collision-energy-induced dissociation for peptide fragmentation on a Q Exactive instrument (Fig. 1a) . To identify the glycan compositions and the amino-acid sequences of intact glycopeptides from MS/MS data sets, we combined charge deconvolution and de-isotoping algorithms 11 to transform the signals of multiply charged fragment ions to the corresponding singly charged m/z values. This shifts fragment ions of the intact peptide with gradually dismembered glycans to higher m/z ranges. The less abundant fragment ions of the peptide-backbone, important for polypeptide sequence identification, remain in the lower mass-range of the MS/MS spectrum. These two 1 IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr. Bohr Gasse 3, A-1030 Vienna, Austria. 2 Institute of Molecular Pathology (IMP), Dr. Bohr Gasse 7, A-1030 Vienna, Austria. 3 GMI, Gregor Mendel Institute of Molecular Plant Biology, Dr. Bohr Gasse 3, A-1030 Vienna, Austria. 4 University of Natural Resources and Life Sciences, Muthgasse 18, A-1190 Vienna, Austria. *These authors contributed equally to this work. Letter reSeArCH regions of the MS/MS spectrum were separated by the prominent feature of the [peptide + HexNAc] + fragment ion (Fig. 1b) . Next, we identified this fragment by iteratively changing the precursor-ion mass of a given MS/MS spectrum by subtracting all glycan masses considered (Supplementary Table 1 ). Upon identification of a putative [peptide + HexNAc] + fragment ion, the MS/MS spectrum was cloned and its precursor-ion mass was set to the mass of the detected fragment ion (Fig. 1b) . To uncover the glycopeptide amino-acid sequences, we searched the processed MS/MS data set against a protein database, using benchmarked MS/MS search engines, considering a single HexNAc moiety as a variable modification to any asparagine, serine, and threonine residue (Fig. 1a) . This analytical pipeline (SugarQb: see Methods) identifies and quantifies intact glycopeptides from complex biological samples. Of note, in all our data analyses and presentation of results, glycan structures were inferred from their monosaccharide composition and known biosynthetic rules for glycans.
We used this approach to investigate the glycoproteome of mouse embryonic stem cells (mESCs, line AN3-12, diploid state). We enriched and fractionated glycopeptides from trypsin-digested wholecell lysates of mESCs using HILIC (25 fractions) and individually analysed them by nano-LC-ESI-MS/MS (using 3 h gradients) (Fig. 1a) . We identified 3,380 unique intact glycopeptides (false discovery rate <1%) 12 , mapping to 786 glycosylation sites of 508 mESC glycoproteins (Fig. 1c) , using MASCOT as the MS/MS search engine. We obtained similar results with other search engines (Extended Data Fig. 1a and Supplementary Table 2 ). Of note, we observed multiple HILIC fractions containing the same glycopeptides. To estimate our coverage of the mESC glycoproteome, we compared our data with the predicted mouse glycoproteome, most of which have never been validated (Fig. 1c) . Of the 3,691 predicted mouse glycoproteins, 1,134 were expressed at FPKM (fragments per kilobase of transcript per million mapped reads) >1 in AN3-12 mESCs. Further analysis indicated approximately 50% coverage of the expressed N-glycoproteome when FPKM > 20 was used as cut-off. Less abundant proteins were detected more sparsely (Fig. 1d) . Thus, our approach uncovered nearly half of the glycoproteins predicted to be expressed in mESCs, and almost doubled the number of experimentally confirmed N-glycosylation sites of the entire mouse glycoproteome (Extended Data Fig. 1b) .
To control for a potential bias towards the identification of particular subsets of N-glycans, we analysed enzymatically released N-glycans of mESC whole-cell lysates by matrix-assisted laser desorption/ ionization-time of flight (MALDI-TOF)-MS. Both methods independently showed that ~ 70% of the mESC glycoproteome are decorated with eight neutral oligo-mannose-type structures (OMTs), whereas the group of complex-type N-glycans represented about 30% of the N-glycome (Fig. 2a and Extended Data Fig. 1c) . We also identified 38 mannose-6-phosphate (M6P)-containing OMT N-glycopeptides (Supplementary Table 3 ), mainly derived from hydrolytic proteins Letter reSeArCH associated with the lysosome by Gene Ontology term enrichment analysis, as expected 4, 13 . Further, we discovered several unanticipated glycoproteins (Fig. 1c) , including nuclear envelope (for example, Emd, Nop56, Tmpo, Rad51ap) and cytosolic proteins (for example, Smg7, Rpl34, Map4k4, Pbxip1) modified with large N-linked OMTs (Supplementary Table 4 and Supplementary Figs 1-8 ). We validated these findings, warranting further investigation, by re-analysing enzymatically de-glycosylated N-glycopeptides and their identification as deamidated nonglycopeptides 7, 14 ( Fig. 2b and Supplementary Table 5 ). Furthermore, in early eluting HILIC fractions we identified mucin-type O-linked glycopeptides (for example, Dag1, Gpc4, Fn1). These glycoproteins are usually inaccessible to conventional glycoproteomic methods 7, 14 and typically require specialized methodology 15 . In the same fractions, we identified serine and threonine residues modified with a single GlcNAc (Supplementary Table 6 ), an important post-translational modification of nuclear and cytosolic proteins 16 . Accordingly, this group of 94 O-GlcNAc proteins was significantly enriched for proteins with nucleic acid binding properties and transcription regulator activity, including the stem cell pluripotency factors Sox2 or Tet2 (ref. 17) . Thus, we uncovered multiple novel O-GlcNAc-decorated proteins, in addition to previously identified nuclear O-GlcNAc-modified proteins from mESCs 18 .
Human embryonic stem cells (hESCs) and mESCs exhibit distinct expression profiles for carbohydrate-related stemness markers 19 . We identified 1,106 unique glycopeptide sequences mapping to 576 glycoproteins in hESCs (Fig. 2c, d ). Similar to mESCs, ~ 70% of the hESC glycoproteome was decorated with oligo-mannose-type N-glycans, whereas complex-type N-glycan structures represented ~ 30% of the population (Fig. 2c) . We observed M6P-containing glycan structures on 58 hESCs glycoproteins and identified several unanticipated glycoproteins ( Fig. 2d and Supplementary Table 7 ). Among those, we detected 79 O-GlcNAc-decorated proteins including the transcription factors SOX2, SP1, PHC1, or GATAD2A (Supplementary Table 8 ). We next compared differential protein glycosylation in mESCs and hESCs. In mESCs, complex-type N-glycans were predominantly terminated with galactose and/or N-acetylhexosamine, whereas those from hESC were mainly sialylated (Fig. 2a, c) . The N-glycans enriched in hESCs relative to mESCs, exemplified by the 2,059, 2,205, and 2,350 dalton (Da) glycan species in Fig. 2c , were reported as hESC-specific N-glycan structures whose abundance gradually decreases upon differentiation 20, 21 . Similarly, the abundance of mESC-specific glycans (that is, 1,971 and 2,117 Da; Fig. 2a ) was reported to decrease during development 20, 22 . We interrogated our comparative ESC glycoproteomics data set for glycoproteins carrying exactly these species-specific stemness-related N-glycan structures and identified 27 
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(1) Letter reSeArCH and 37 plasma membrane proteins in mESCs and hESCs (Fig. 2a, c) , respectively, most of them implicated in cell-to-cell signalling and cell interactions, as well as embryonic development.
Next, we compared the glycosylation profiles of 237 glycoproteins shared between mESCs and hESCs ( Fig. 2e and Supplementary Table 9 ). For example, Lamp1, a major stage-specific embryonic antigen-1 (SSEA-1) reactive protein in mouse neuronal stem cells 23 , was detected in both species (Fig. 2f) . SSEA-1 (Lewis X, CD15) is a mouse-specific pluripotency marker which relates to a specific α-1,3-fucosylated carbo hydrate epitope (Fig. 3a) . Thus, we interrogated N-glycosylation sites of Lamp1 for this epitope and identified glycan compositions indicating multiply fucosylated hybrid-type N-glycans, for instance at Asn252 of mESC Lamp1 (Fig. 2g) . Unexpectedly, we also observed multiply fucosylated glycan compositions at the orthologous glycosylation site of LAMP1 in hESCs, Asn261 (Fig. 2g) , consistent with previous work suggesting that hESCs synthesize Lewis X complex-type N-glycans, despite being negative for SSEA-1 (ref. 20) . Comparative analysis of the site-specific glycan profiles revealed subtle glycan compositional differences on these proteins. Whereas Asn252 of mouse Lamp1 exhibited fucosylated hybrid-type N-glycans, Asn261 of human LAMP1 carried fucosylated bi-antennary N-glycan species (Fig. 2f, g ). Thus, both mESCs and hESCs exhibit fucosylated glycans, even at the orthologous site on the same protein. But since the core structure of these glycans differs, the anti-SSEA-1 antibody does not recognize the Lewis X epitope on bi-antennary N-glycans.
We and others 5, 6, 24 previously established a critical sugar code whereby the presence of Lewis X glycan structures confers sensitivity to the bioweapon ricin. However, the proteins carrying this carbohydrate epitope and whether these glycoproteins were involved in ricin toxicity were unclear. In mESCs, α-1,3-fucosyltransferase Fut9 and the fucose transporter Slc35c1 are essential for the synthesis of the Lewis X carbohydrate epitope (Fig. 3a) 25,26 . Thus, we compared the relative glycopeptide abundances between Slc35c1 and Fut9 mutant and control mESC sister clones, genetically repaired by the inversion of a gene trap cassette, using an in vitro stable isotope labelling technique for peptides 10, 27 and analysed by nLC-ESI-MS/MS ( Fig. 3b  and Supplementary Table 10 ). Making use of an in vitro stable isotope labelling-technique and MS/MS-based quantitation also allowed for the comparative analysis of glycopeptides despite overlapping HILIC fractions.
As expected, OMT-decorated glycoproteins, M6P-containing OMTs, and O-GlcNAc proteins were unaffected by loss of Slc35c1 and Fut9 (Fig. 3c) . We also did not detect significant changes in overall protein expression in the mutant cells (Extended Data Fig. 2a-c) . However, deletion of Slc35c1 abolished fucosylation of N-and O-glycoproteins, resulting in a reciprocal increase in the corresponding non-fucosylated glycan structures (Fig. 3c and Supplementary Table 10 ). These changes are exemplified by the glycosylation profiles of Igf2r (Fig. 3d) . Igf2r (cation-independent mannose 6-phosphate receptor) 13 has 20 potential N-glycosylation sites; only three had been experimentally confirmed previously 7 . We not only confirmed seven other N-glycosylation sites, but also uncovered complex-type N-glycan structures at Asn430, Asn704, and Asn1532 of Igf2r affected by inactivation of Slc35c1. Only those at Asn1532 were a target of Fut9. The glycans affected by the loss of Fut9 were a subset of those targeted by Slc35c1 (Fig. 3c, d and Supplementary Tables 11 and 12 ): 88 glycoproteins were sensitive to loss of Slc35c1, of which 33 were also targets of Fut9. Thus, our unbiased method detects specific changes to glycosylation profiles.
Both Fut9 and Slc35c1 knockout (KO) cell lines were ricin resistant 5, 6 ; therefore we hypothesized that glycoproteins affected by both mutations might be required for ricin sensitivity. We generated mutant GFPlabelled clones for 24 candidate genes and their respective repaired 
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Letter reSeArCH mCherry-labelled sister clones (Fig. 4a) . Igf2r, Slc39a14, Itgb1, Lamp1, Ly75, and Hs2st1 mutant mESCs displayed improved survival in the presence of ricin compared with the sister clones ( Fig. 4a and Extended Data Fig. 3 ). CRISPR/Cas9-mediated disruption of these genes in human HEK293FT cells also increased their resistance to ricin (Fig. 4b) . Further, we reconstituted an Igf2r mutant mouse SCC-VII squamous cell carcinoma line (Igf2r KO) 28 with either wild-type (WT) human IGF2R (IGF2R) or a mutant version inactive for M6P binding (IGF2R*) 29 . As ricin itself exhibits OMT N-glycan structures 30 , we used the IGF2R* mutant cell line to exclude possible binding of ricin to IGF2R via M6P. Parental Igf2r KO cells exhibited significant resistance to ricin treatment compared with IGF2R-and IGF2R*-expressing cells (Fig. 4c-e) , indicating that human IGF2R confers sensitivity to ricin, independent of its capacity to bind M6P. Therefore, our comparative glycoproteomics approach uncovered proteins whose fucosylation is required for ricin toxicity.
In summary, we report a glycoproteomics method to identify intact glycopeptides, and directly map and quantify changes in protein glycosylation at a proteome scale. Our analysis of the hESC and mESC glycoproteomes nearly doubled the number of experimentally confirmed glycosylation sites and uncovered multiple novel glycosylated proteins, including evolutionarily conserved and species-specific glycan modifications of mouse and human stemness factors. We have determined the specificity of our approach by quantitatively delineating the glycoproteomes of ricin-resistant Fut9 and Slc35c1 mutants, which revealed new players orchestrating ricin toxicity. We anticipate that this freely available data-interpretation tool will be widely applied and will democratize glycoproteomics, enabling proteome-wide studies of this fundamental building block of biology in virtually all species.
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MethOdS
Cell lines. mESCs (clone AN3-12) 5 were cultured in DMEM supplemented with 10% fetal bovine serum (FCS), penicillin-streptomycin, non-essential amino acids, sodium pyruvate (1 mM), l-glutamine (2 mM), β-mercaptoethanol (0.1 mM), and LIF (20 μg ml
−1
). SCC-VII and HEK293FT cells were cultured in DMEM supplemented with 10% FCS (fetal calf serum), penicillin-streptomycin, and l-glutamine. hESCs (line H9) were cultured in 20% O 2 conditions on irradiated mouse embryonic fibroblast feeder layers in hESC medium (KO-DMEM or DMEM-F12 (Gibco 121660), 15% KO serum replacement (Gibco 10828), 1 mM glutamine (Invitrogen), 1% non-essential amino acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), 8 ng ml −1 βFGF (Peprotech)). H9 cultures were passaged every 5-7 days and the medium changed every day. Igf2r KO mouse SCC-VII cells (parental clone) and Igf2r KO SCC-VII cells reconstituted with human WT (SCC-VII/IGF2R wt-3) and mutant IGF2R (SCC-VII/IGF2R Dom3/9mut-1) have been previously described 29 .
Mouse AN3-12 ESC lines were generated in our laboratory and fully characterized and authenticated as described 5 . Mouse SCC-VII cells were originally isolated by R. P. Hill (Ontario Cancer Institute, Toronto, Canada), obtained and provided by L. Mach (BOKU, Vienna), and authenticated by the absence of endogenous Igf2r and the presence of a functional transgene (namely Igf2r, Igf2r*). HEK293FT cells were obtained from an in-house source and functionally authenticated by positive selection for pCMVSPORT6TAg.neo expression. H9 human ESCs were obtained directly from the supplier (WiCell, Wisconsin, USA) and thus not further authenticated.
All cell lines were tested negative for mycoplasma contamination. No cell line listed by ICLAC was used. Glycoproteomic sample preparation and protein digestion. mESC and hESC cultures were washed three times with PBS, then incubated for 5 min with PBS containing 1 mM EDTA and centrifugated at 900 g. The supernatant was removed and the cell pellets were immediately lysed by the addition of freshly prepared 10 M urea in 120 mM triethylammonium bicarbonate buffer (TEAB, Sigma) to a final concentration of 8 M urea in 100 mM TEAB and brief ultra-sonication (ultrasonic processor UP100H, Hielscher). mESC-derived samples were reduced (final concentration 5 mM Tris(2-carboxyethyl)phosphine hydrochloride, 30 min) and alkylated (final concentration 10 mM methyl-methanethiosulfonate, 30 min). hESC samples were reduced using a final concentration of 10 mM 1,4-dithioerythritol and alkylated using a final concentration of 20 mM 2-iodoacetamide. Protein concentrations were measured (BCA Protein Assay Kit, Pierce) and 1 mg protein per sample digested with 10 μg endoproteinase Lys-C (Wako) for 8 h at 37 °C. Subsequently, the samples were diluted with water to 6 M urea in 75 mM TEAB and incubated with 1 U Benzonase (Merck KGaA) for 1 h at 37 °C. The samples were further diluted to 4 M urea in 50 mM TEAB and incubated with 10 μg modified porcine trypsin (sequencing grade, Promega) for 12 h at 37 °C. After TMT-6plex-labelling (performed according to the supplier's manual), the pH of the individual samples was adjusted to 2 by the addition of 10% trifluoroacetic acid (TFA). The samples were pooled in equal amounts, desalted using reverse-phase solid-phase extraction cartridges (Sep-Pak C-18, Waters) and completely dried under vacuum. Before glycopeptide enrichment, the samples were digested with 1 U alkaline phosphatase (from calf intestine, Roche), desalted using Sep-Pak C-18 cartridges, and dried under vacuum. N-glycan analyses. N-glycans were enzymatically released from desalted tryptic digests of ESCs using PNGaseF (from Elizabethkingia meningoseptica, Sigma), labelled with 2-aminobenzoic acid by reductive amination using sodium borohydride as reducing agent, essentially as described 33 . The N-glycans labelled with 2-aminobenzoic-acid were then measured by MALDI-TOF-MS (4800 MALDI-TOF/TOF Analyser, AB Sciex) operated in negative mode, using DHB as the matrix component. Glycopeptide enrichment. Glycopeptides were enriched using ion-pairing HILIC. The dry samples were taken up in 100 μl 75% acetonitrile containing 0.1% TFA, and subjected to chromatographic separation on a TSKgel Amide-80 column (4.6 mm × 250 mm, particle size 5 μm) using a linear gradient from 0.1% TFA in 80% acetonitrile to 0.1% TFA in 40% acetonitrile over 35 min (Dionex Ultimate 3000, Thermo). The 25 collected fractions were dried in a vacuum concentrator. For validation experiments identifying de-N-glycosylated peptides, aliquots of these fractions were re-suspended in 100 mM Tris buffer, pH 8.0, and incubated with 1 U PNGaseF for 12 h at 37 °C. Before LC-MS/MS analysis, the PNGaseF reaction was quenched by adjusting the pH of the individual samples to 2 by the addition of 10% TFA. LC-MS/MS. The 25 ion-pairing HILIC fractions were individually analysed by LC-MS/MS. The samples were separated by reversed-phase chromatography (75 μm × 250 mm PepMap C18, particle size 5 μm, Thermo), developing a linear gradient from 2% acetonitrile to 80% acetonitrile in 0.1% formic acid, within 3 h (RSLC nano, Dionex -Thermo Fisher Scientific) and analysed by MS/MS, using electrospray-ionization quadrupole Fourier-transformed tandem mass-spectrometry (Q Exactive, Thermo) and higher collision-induced dissociation. The instrument was operated in positive mode and set to the following acquisition parameters: MS1 resolution = 70,000; MS1 AGC-target = 1 × 10 6 ; MS1 maximum inject time = 60 ms; MS1 scan range = 350-2,000 m/z; MS2 resolution = 70,000; MS2 AGC-target = 1 × 10 6 ; maximum inject time = 256 ms; TopN = 10; isolation window = 1.2 m/z; fixed first mass = 120 m/z; normalized collision energy = 35; underfill ratio = 2.5%; peptide match = on; exclude isotopes = on; dynamic exclusion = 10 s. Data analysis. All MS/MS data were processed and analysed using Xcalibur 2.2 (version 2.2.48, Thermo) and Proteome Discoverer 1.4 (PD 1.4.0.288, Thermo). MS/MS data processing and automated glycopeptide identification. MS/MS spectra were extracted from the.raw file format using the generic Spectrum Exporter Node of PD 1.4 (settings: minimum precursor mass = 350 Da; maximum precursor mass = 10,000 Da; minimum peak count = 5, S/N threshold 1.5), charge-deconvoluted, and de-isotoped ('MS2 Spectrum Processor' , in-house implementation of the algorithm described 11 , available as PD 1.4 Node at http:// www.imba.oeaw.ac.at/sugarqb), and were then scored with respect to the abundance of glycosylation-related reporter ions (G-score). As a general indicator for the presence of glycan-specific reporter ions within a given MS/MS spectrum, the G-score was calculated as the reciprocal value of the negative logarithm of the summed fractions of the normalized intensities of the reporter ions (that is, 126.05496, 138.05496, 144.06552, 163.06007, 168.06552, 186.07608, 204.08665, 274.09270, 292.10267 a.m.u., mass-precision 10 p.p.m.) and their respective rank in the spectrum. We empirically determined that MS/MS spectra with a G-score greater than 0.4 were derived from glycopeptides: + fragment ion was detected (with a fragment mass tolerance of 10 p.p.m.), the spectrum was duplicated, with the original precursor-ion mass being set to the mass of the potential [peptide + HexNAc] + fragment ion. For peptide sequence identification, the pre-processed MS/MS data were then searched against the Uniprot mouse reference proteome set (http://uniprot.org, 47,435 entries; concatenated forward and reverse database), using MASCOT (Matrix Science Ltd, version 2.2.07), SEQUEST-HT (built-in version of PD 1.4), and X!Tandem (Sledgehammer, version 2013.09.01). The parameters for all MS/MS search engines were set to trypsin as protease, allowing for maximally two missed cleavage sites, a precursor mass tolerance of 10 p.p.m., a fragment mass tolerance of 25 millimass units, the fixed modification of methylthiolated or carbamidomethylated cysteine, the variable modifications of oxidation (methionine), de-amidation (asparagine and glutamine), and hexosamine (asparagine, serine and threonine), and TMT-6plex (N terminus and lysine). The resulting peptide spectrum matches were manually filtered (search-engine rank 1, peptide length greater than 6, and at least one HexNAc-modified residue) and filtered to 1% false discovery rate, using the target-decoy approach 12 . Site localization of N-glycans was performed using ptmRS (in-house developed 34 and available as PD 1.4 Node at http://www.imba.oeaw.ac.at/sugarqb), scoring the characteristic loss of 120.042259 Da from glycosylated asparagine as the diagnostic ion. Insertional mutagenesis in mESCs. Haploid mESCs were generated previously 5 and used for reversible mutagenesis (that is, derivation of genetrap-harbouring KO and genetically repaired sister cell lines). mESCs harbouring a genetrap in introns of Slc35c1 and Fut9, as well as Lewis X-containing candidate mutant embryonic stem cell lines, were generated as described 5 . For the reversion of the genetrap, clones carrying the genetrap vector were infected with retroviruses carrying mCherry together with Cre recombinase. Retroviruses carrying GFP alone were used to label KO cells. For single-cell clones, cells were transiently transfected with a plasmid encoding Cre recombinase as well as GFP; sorted and single-cell clones were then analysed using PCR. The orientation of the splice acceptor was determined using a three-primer-containing amplification system, consisting of a fragment binding first forward primer or the inverse 
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Primary antibodies specific for IGF2R (anti M6PR (cation independent) antibody (MEM-238), abcam ab8093) were validated by the supplier and confirmed by specific reactivity against IGF2R in an over-expressing versus a IGF2R deficient cell line (i.e. SCC-VII/IGF2R, SCC-VII/IGF2R* versus parental SCC-VII).
The anti Oct-3/4 antibody (Clone 40/Oct-3 (RUO), BD Transduction Laboratories, No.611203, 1:300) and anti-SSEA-1 (CD15, Lewis X; PE conjugated, clone: MC-480, ebioscience 12-8813-41, 1:300) antibody were validated by the suppliers.
